Blood Gone Bad - Working Through Common Hematologic Issues Encountered on the Pediatric Inpatient Unit-Slides

Slides
Pdf Summary
This presentation focuses on hematology issues in hospitalized children, particularly cytopenias (anemia, thrombocytopenia, neutropenia) and hospital-acquired venous thromboembolism (HA-VTE).<br /><br />Cytopenias are common in hospitalized kids, caused by factors such as frequent blood draws, inflammation, infection, marrow suppression, immune destruction, bleeding, and medications. Neutropenia is defined by an absolute neutrophil count (ANC) below age-specific thresholds, with categories ranging from mild to severe. Assessing risk of serious bacterial infection involves evaluating whether the child appears ill and identifying risk factors like prolonged neutropenia, immunocompromise, central lines, and co-morbidities. Studies show immunocompetent children with neutropenia rarely have serious bacterial infections. Management depends on clinical assessment: well-appearing low-risk patients may be managed as outpatients without antibiotics; sick or unstable children require inpatient care with broad-spectrum antibiotics and monitoring. Drug-induced and viral neutropenia (e.g., RSV, COVID-19) are common. More extensive workup is reserved for recurrent, severe, or unusual infections or associated systemic signs. The "Duffy null" phenotype, common in African or Middle Eastern populations, causes lower ANC but no increased infection risk and should be considered to avoid unnecessary interventions.<br /><br />HA-VTE incidence is rising in hospitalized children, with risk factors including central venous catheters (especially peripherally inserted), age (infants, teens), ICU stay, mechanical ventilation, cancer, infection, inflammation, immobility, and surgery. Management includes anticoagulation—historically at least 3 months but recent data support shorter courses (6 weeks) for provoked clots if risk factors are resolved. Options include heparins, vitamin K antagonists, and newer direct oral anticoagulants (e.g., rivaroxaban, dabigatran) with favorable efficacy and safety profiles. Line-associated clots do not always require line removal if the line is functioning and needed. Routine thrombophilia testing is generally not recommended except for recurrent events or positive family history, as it seldom changes management or predicts recurrence.<br /><br />Preventive guidelines are still evolving, with ongoing studies focusing on high-risk populations. In summary, neutropenia in previously healthy children is often benign and transient, and HA-VTE is increasingly recognized but manageable with modern anticoagulation strategies. Clinical context guides diagnosis, treatment, and testing decisions.
Keywords
hematology
hospitalized children
cytopenias
anemia
thrombocytopenia
neutropenia
hospital-acquired venous thromboembolism
HA-VTE
anticoagulation
Duffy null phenotype